A Novel Class of Norovirus Inhibitors Targeting the Viral Protease with Potent Antiviral Activity In Vitro and In Vivo.
Animals
Caliciviridae Infections
/ drug therapy
Cell Line
Cytopathogenic Effect, Viral
/ drug effects
Drug Resistance, Viral
Isoxazoles
/ pharmacology
Microbial Sensitivity Tests
Molecular Docking Simulation
Mutation
Norovirus
/ drug effects
Peptide Hydrolases
/ genetics
Phenylalanine
/ analogs & derivatives
Pyrrolidinones
/ pharmacology
RNA, Viral
/ metabolism
Replicon
Small Molecule Libraries
Valine
/ analogs & derivatives
Viral Protease Inhibitors
/ chemistry
Virus Replication
/ drug effects
Zebrafish
/ virology
Caliciviridae
antivirals
danio rerio
infection
small molecule
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
16 09 2021
16 09 2021
Historique:
received:
17
08
2021
revised:
08
09
2021
accepted:
11
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
9
2
2022
Statut:
epublish
Résumé
Human noroviruses (HuNoVs) are the most common cause of viral gastroenteritis resulting annually in ~219,000 deaths and a societal cost of ~USD 60 billion, and no antivirals or vaccines are available. Here, we assess the anti-norovirus activity of new peptidomimetic aldehydes related to the protease inhibitor rupintrivir. The early hit compound
Identifiants
pubmed: 34578432
pii: v13091852
doi: 10.3390/v13091852
pmc: PMC8472913
pii:
doi:
Substances chimiques
Isoxazoles
0
Pyrrolidinones
0
RNA, Viral
0
Small Molecule Libraries
0
Viral Protease Inhibitors
0
Phenylalanine
47E5O17Y3R
Peptide Hydrolases
EC 3.4.-
Valine
HG18B9YRS7
rupintrivir
RGE5K1Q5QW
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Lancet Oncol. 2009 Jan;10(1):61-71
pubmed: 19111246
mBio. 2019 Oct 1;10(5):
pubmed: 31575769
Antimicrob Agents Chemother. 1999 Oct;43(10):2444-50
pubmed: 10508022
J Virol. 2013 Nov;87(21):11798-805
pubmed: 23986582
J Biol Chem. 2015 Nov 13;290(46):27841-53
pubmed: 26363064
Antiviral Res. 2006 Sep;71(2-3):391-6
pubmed: 16675037
J Med Chem. 2020 May 14;63(9):4562-4578
pubmed: 32045235
Viruses. 2019 Feb 25;11(2):
pubmed: 30823509
Science. 2016 Sep 23;353(6306):1387-1393
pubmed: 27562956
Virology. 2010 Oct 10;406(1):138-48
pubmed: 20674956
Antimicrob Agents Chemother. 2005 Feb;49(2):619-26
pubmed: 15673742
Science. 2020 Jun 19;368(6497):1331-1335
pubmed: 32321856
J Virol. 2006 May;80(10):5050-8
pubmed: 16641296
J Infect Dis. 2018 Oct 20;218(11):1753-1758
pubmed: 30085019
J Virol. 2019 Mar 5;93(6):
pubmed: 30626675
PLoS Pathog. 2019 Sep 19;15(9):e1008009
pubmed: 31536612
J Infect Dis. 2007 Mar 1;195(5):665-74
pubmed: 17262707
Biochem Biophys Res Commun. 2012 Aug 10;424(4):777-80
pubmed: 22809499
Nat Protoc. 2021 Apr;16(4):1830-1849
pubmed: 33837302
PLoS One. 2016 Apr 26;11(4):e0151219
pubmed: 27115736
Biotechniques. 2004 May;36(5):878-85
pubmed: 15152609
J Virol. 2012 Nov;86(21):11754-62
pubmed: 22915796
F1000Res. 2015 Jan 12;4:9
pubmed: 26097685
Virology. 2003 Apr 10;308(2):216-24
pubmed: 12706072
Antimicrob Agents Chemother. 2014 Aug;58(8):4675-81
pubmed: 24890597
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29530860